NL-OMON36726
Completed
N/A
A One-Way Drug-Drug Interaction Study to Assess the Effect of Ritonavir-boosted Atazanavir on the Pharmacokinetics, Safety and Tolerability of BMS-790052 in Healthy Subjects - BMS-790052/ritonavir-boosted atazanavir drug-drug interaction study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hepatitis C
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 14
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 18\-49 years, inclusive
- •BMI: 18\.0 \- 32\.0 kg/m2, inclusive
- •Women of child bearing potential should use adequate contraception (e.g., double barrier method) until at least 4 weeks after last dose of study medication
Exclusion Criteria
- •\- Any significant acute or chronic medical illness.
- •\- Current or recent (within 3 months of study drug administration) gastrointestinal disease indicated as clinically relevant by the Medical Investigator.
- •\- Any major surgery within 4 weeks of study drug administration.
- •\- Any gastrointestinal surgery that could impact upon the absorption of study drug.
- •\- Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 90 days of study drug administration.
- •\- Blood transfusion within 90 days of study drug administration.
- •\- Inability to tolerate oral medication.
- •\- Inability to swallow oral medication in the form of tablets or capsules.
- •\- Inability to be venipunctured and/or tolerate venous access.
- •\- Smoking more than 5 cigarettes per day.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTSHepatitis Cviral liver inflammation10047438NL-OMON36747Bristol-Myers Squibb17
Not Yet Recruiting
Phase 1
A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy VolunteersACTRN12624001072505ura Bio18
Not Yet Recruiting
N/A
A phase 1 study to evaluate drug-drug interactions of Bojungikgitang with Clopidogrel, Atorvastatin, and Fimasartan/Amlodipine in healthy adult volunteersKCT0007296Kyunghee University-industry Cooperation Foundation42
Completed
N/A
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancerprostate cancer10036958NL-OMON44408Johnson & Johnson Pharmaceutical10
Completed
N/A
A study to assess pharmacokinetic interactions by evaluating the effect of red ginseng in healthy Korean adultsSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0002418Kyungpook National University Hospital15